SCHEMBL14711337

SCHEMBL14711337

CCOC(=O)c1c(-c2ccccc2)noc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.56
ADORA3 P0DMS8 4/20 0.56
L3MBTL1 Q9Y468 2/20 0.54
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
PTBP1 P26599 1/20 0.54
NPC1 O15118 2/20 0.52
GAA P10253 2/20 0.52
MAPT P10636 1/20 0.52
RAB9A P51151 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ATM Q13315 1/20 0.52
CACNA1F O60840 1/20 0.52
CACNA1D Q01668 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536297 0.86 TSHR (0.74) POLBALOX15TSHRMAPK1L3MBTL1
SCHEMBL31526266 0.84 PTGS1 (0.72) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL14711335 0.84 POLB (0.57) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL2776718 0.84 TSHR (0.54) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL2776267 0.83 TSHR (0.70) POLBALOX15TSHRMAPK1L3MBTL1
SCHEMBL3940991 0.83 POLB (0.56) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL4088587 0.83 ALDH1A1 (0.59) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL2761365 0.83 PTGS1 (0.62) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL535741 0.82 TSHR (0.55) POLBALOX15TSHRMAPK1ADORA3
SCHEMBL2775786 0.82 TSHR (0.52) POLBALOX15TSHRMAPK1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 POLB 4247/4885ALOX15 183/4885TSHR 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.